Mast cell disorders: diagnosis & management

Work-up of suspected mast cell disease from an elevated baseline tryptase or recurrent mast-cell-activation symptoms / unexplained anaphylaxis: separates hereditary α-tryptasemia and MCAS from clonal systemic mastocytosis, stages SM by B- and C-findings, and routes each to its management ledger, anti-mediator symptom control, anaphylaxis prevention (lifelong venom immunotherapy), and KIT-inhibitor cytoreduction for advanced disease. Wires in the tryptase 20%+2, REMA, and WHO/ICC SM-criteria calculators.

Evidence tier: Expert consensus. Reflects expert-consensus criteria, not a prospectively validated instrument. Apply clinical judgment and local policy.

Decision points

  • Is clonal mast cell disease likely?
  • Stage systemic mastocytosis, B- and C-findings

Do-not-miss pitfalls

  • An elevated baseline tryptase is most often hereditary α-tryptasemia (TPSAB1 copy-number gain), not mastocytosis, confirm with blood KIT D816V and the REMA score before committing a patient to a bone marrow biopsy or a mastocytosis label.
  • MCAS is over-diagnosed: it requires ALL THREE consensus criteria, episodic symptoms in ≥2 organ systems, an event-related tryptase rise ≥ (1.2 × baseline) + 2 ng/mL, and a documented response to anti-mediator therapy. Chronic non-episodic symptoms with no tryptase rise do not meet criteria.
  • In any patient with mastocytosis and Hymenoptera anaphylaxis, venom immunotherapy is LIFELONG, fatal sting reactions have occurred after stopping it; the usual 5-year stopping rule does not apply.
  • B-findings (high mast-cell burden) define smoldering SM and warrant closer monitoring, but they are NOT organ dysfunction, do not start cytoreduction for B-findings alone. Only C-findings (cytopenias, hepatopathy, malabsorption with weight loss, large osteolysis) define aggressive disease.
  • Avapritinib carries an intracranial-hemorrhage risk, it is not recommended when platelets are <50 × 10⁹/L, and patients should report severe headache or new neurologic symptoms immediately.
  • Mastocytosis-associated osteoporosis is common and often silent, survey bone density and treat with bisphosphonates; do not overlook bone disease while focused on mediator symptoms.
  • Every patient with a mast cell disorder and any anaphylaxis history needs ≥2 epinephrine autoinjectors and a written action plan, and should avoid identified degranulation triggers (which may include certain NSAIDs, opioids, radiocontrast, and perioperative agents).
  • Cutaneous mastocytosis in children usually regresses and rarely needs systemic work-up; new maculopapular (urticaria pigmentosa) lesions in an adult warrant evaluation for underlying systemic mastocytosis.

Evidence & citations

  1. Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(7):1097-1116. PMID 37309222
  2. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-225. International consensus proposal (MCAS diagnostic criteria)
  3. AYVAKIT (avapritinib) US prescribing information. Blueprint Medicines; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf
  4. RYDAPT (midostaurin) US prescribing information. Novartis; 2017. FDA prescribing information
  5. González-de-Olano D, Álvarez-Twose I, Esteban-López MI, et al. Venom immunotherapy in patients with mastocytosis and Hymenoptera venom anaphylaxis. Immunotherapy. 2011;3(5):641-654. PMID 21554093

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.